Home > Healthcare > Pharmaceuticals > Finished Drug Form > sirolimus market
Get a free sample of Sirolimus Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Sirolimus Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Based on application, the market is bifurcated into organ transplant rejection, lymphangioleiomyomatosis (LAM), and sirolimus coated balloons and catheter devices. The organ transplant rejection segment held the market size of USD 120.8 million in 2023.
Based on route of administration, the sirolimus market is segmented into injection and tablets. The tablets segment is anticipated to reach a market size of USD 211.1 million by 2032.
Based on dosage, the sirolimus market is segmented into 0.5mg, 1mg, and 2mg. The 1mg segment held a market size of USD 120.9 million in 2023.
Based on distribution channel, the sirolimus market is segmented hospital pharmacy, retail pharmacy, and online pharmacy. The hospitals pharmacy segment expected reach a market size of USD 165.1 million by 2032.
North America sirolimus market accounted for USD 109.7 million revenue in 2023 and is predicted to witness substantial market growth.
Apotex Inc., Concord Biotech, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Livzon Pharmaceuticals Group Inc., Pfizer Inc., Tiefenbacher API + Ingredients GmbH & Co. KG, Torrent Pharmaceuticals Ltd., and Zydus Group, are some of the major sirolimus companies worldwide.
North America sirolimus industry exceeded 109.7 million in 2023 due to the presence of state-of-the-art medical facilities, research institutions, and pharmaceutical companies in the region.
The organ transplant rejection segment recorded USD 120.8 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to its immunosuppressive properties and anti-proliferative effects on vascular smooth muscle cells.
Sirolimus market size crossed USD 270.7 million in 2023 and is expected to reach over USD 370.4 million by 2032 owing to the increasing prevalence of organ transplants and promising pipeline for different indications worldwide.